Drugs@FDA: FDA-Approved Drugs
Abbreviated New Drug Application (ANDA): 219602
Company: GLENMARK SPECLT
Company: GLENMARK SPECLT
| Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
|---|---|---|---|---|---|---|---|
| FLUTICASONE PROPIONATE | FLUTICASONE PROPIONATE | 0.044MG/INH | AEROSOL, METERED;INHALATION | Prescription | AB | No | No |
Original Approvals or Tentative Approvals
| Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
|---|---|---|---|---|---|---|---|
| 03/03/2026 | ORIG-1 | Approval | STANDARD |
Label is not available on this site. |
FLUTICASONE PROPIONATE
AEROSOL, METERED;INHALATION; 0.044MG/INH
TE Code = AB
| Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | RLD | TE Code | Application No. | Company |
|---|---|---|---|---|---|---|---|---|
| FLOVENT HFA | FLUTICASONE PROPIONATE | 0.044MG/INH | AEROSOL, METERED;INHALATION | Prescription | Yes | AB | 021433 | GLAXO GRP LTD |
| FLUTICASONE PROPIONATE | FLUTICASONE PROPIONATE | 0.044MG/INH | AEROSOL, METERED;INHALATION | Prescription | No | AB | 219602 | GLENMARK SPECLT |